AR069849A1 - Derivados de heteroarilo como antagonistas de receptor de orexina - Google Patents
Derivados de heteroarilo como antagonistas de receptor de orexinaInfo
- Publication number
- AR069849A1 AR069849A1 ARP080105570A ARP080105570A AR069849A1 AR 069849 A1 AR069849 A1 AR 069849A1 AR P080105570 A ARP080105570 A AR P080105570A AR P080105570 A ARP080105570 A AR P080105570A AR 069849 A1 AR069849 A1 AR 069849A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- halogen
- phenyl
- heteroaryl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
La presente se refiere a compuestos de la formula (1) en la que Ar es un grupo arilo o heteroarilo sustituido o sin sustituir, dicho grupo arilo o heteroarilo puede estar sustituido por uno o más sustituyentes R2; R2 es hidroxi, halogeno, alquilo inferior, alquilo inferior sustituido por halogeno, alcoxi inferior, alcoxi inferior sustituido por halogeno, C(O)-alquilo inferior, nitro, NR'Rö, ciano, S-alquilo inferior, SO2-alquilo inferior, cicloalquilo, heterocicloalquilo, feniloxi, benciloxi, fenilo, NH-fenilo o heteroarilo, dicho grupo fenilo o heteroarilo está sin sustituir o sustituido por uno o más sustituyentes elegidos entre alquilo inferior y halogeno; R'/R'' con independencia entre sí son hidrogeno o alquilo inferior; R1 es hidrogeno o alquilo inferior; Het es un resto heteroarilo sin sustituir o sustituido por uno o más sustituyentes elegidos entre R3; R3 es hidroxi, halogeno, =O, alquilo inferior, alquilo inferior sustituido por halogeno, alcoxi inferior, fenilo, alcoxi inferior sustituido por halogeno, nitro, ciano, SO2-alquiIo inferior, cicloalquilo o heterocicloalquilo; n es el numero 1 o 2; o a sales de adicion de ácido farmacéuticamente aceptables, enantiomeros opticamente puros, racematos o mezclas diastereoméricas de los mismos. Se ha encontrado que los compuestos de la formula (1) son antagonistas de receptor de orexina y los compuestos en cuestion pueden ser utiles para el tratamiento de la apnea nocturna, la narcolepsia, el insomnio, la parasomnia, el síndrome de la diferencia horaria (jet Iag), el trastorno del ritmo circadiano o los trastornos del sueno asociados con enfermedades neurologicas. Reivindicacion 1: Un compuesto de la formula (1) en la que Ar es un grupo arilo o heteroarilo sustituido o sin sustituir, dicho grupo arilo o heteroarilo puede estar sustituido por uno o más sustituyentes R2; R2 es hidroxi, halogeno, alquilo inferior, alquilo inferior sustituido por halogeno, alcoxi inferior, alcoxi inferior sustituido por halogeno, C(O)-alquilo inferior, nitro, NR'R'', ciano, S-alquilo inferior, SO2-alquilo inferior, cicloalquilo, heterocicloalquilo, feniloxi, benciloxi, fenilo, NH-fenilo o heteroarilo, dicho grupo fenilo o heteroarilo está sin sustituir o sustituido por uno o más sustituyentes elegidos entre alquilo inferior y halogeno; R'/R'' con independencia entre sí son hidrogeno o alquilo inferior; R1 es hidrogeno o alquilo inferior; Het es un resto heteroarilo sin sustituir o sustituido por uno o más sustituyentes elegidos entre R3; R3 es hidroxi, halogeno, =O, alquilo inferior, alquilo inferior sustituido por halogeno, alcoxi inferior, fenilo, alcoxi inferior sustituido por halogeno, nitro, ciano, SO2-alquilo inferior, cicloalquilo o heterocicloalquilo; n es el numero 1 o 2; o sales de adicion de ácido farmacéuticamente aceptables, enantiomeros opticamente puros, racematos o mezclas diastereoméricas del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07150294 | 2007-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069849A1 true AR069849A1 (es) | 2010-02-24 |
Family
ID=40568638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105570A AR069849A1 (es) | 2007-12-21 | 2008-12-19 | Derivados de heteroarilo como antagonistas de receptor de orexina |
Country Status (14)
Country | Link |
---|---|
US (1) | US7897627B2 (es) |
EP (1) | EP2234999A1 (es) |
JP (1) | JP5395808B2 (es) |
KR (1) | KR101204213B1 (es) |
CN (1) | CN101903372B (es) |
AR (1) | AR069849A1 (es) |
AU (1) | AU2008340421B2 (es) |
BR (1) | BRPI0821141A2 (es) |
CA (1) | CA2705411A1 (es) |
CL (1) | CL2008003787A1 (es) |
IL (1) | IL205665A (es) |
PE (1) | PE20091173A1 (es) |
TW (1) | TW200930362A (es) |
WO (1) | WO2009080533A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
AU2008281399A1 (en) * | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
EP2207778A2 (en) * | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
BRPI0906799A2 (pt) * | 2008-01-11 | 2015-07-14 | Hoffmann La Roche | Moduladores para amiloide beta |
ES2385699T3 (es) * | 2008-02-21 | 2012-07-30 | Actelion Pharmaceuticals Ltd. | Derivados de 2-aza-biciclo-[2,2,1]heptano |
KR101247840B1 (ko) | 2008-02-22 | 2013-03-26 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타 조절제 |
DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
EP2318367B1 (en) * | 2008-04-30 | 2013-03-20 | Actelion Pharmaceuticals Ltd. | Piperidine and pyrrolidine compounds |
DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
ES2386526T3 (es) | 2008-07-29 | 2012-08-22 | F. Hoffmann-La Roche Ag | Pirrolidin-3-ilmetilaminas, como antagonistas de orexina |
WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
MX2011004954A (es) * | 2008-11-10 | 2011-05-30 | Hoffmann La Roche | Moduladores heterociclicos de gamma-secretasa. |
PT2361250E (pt) | 2008-12-22 | 2013-11-11 | Merck Patent Gmbh | Novas formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabrico das mesmas |
WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
PL2491038T3 (pl) | 2009-10-23 | 2016-10-31 | Dwupodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny | |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
AR088352A1 (es) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
RU2014136339A (ru) | 2012-02-07 | 2016-03-27 | Иолас Терапьютикс, Инк. | Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
TW201444821A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
GB201318222D0 (en) * | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
LT3077391T (lt) * | 2013-12-04 | 2018-10-25 | Idorsia Pharmaceuticals Ltd | Benzimidazolo prolino darinių panaudojimas |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
ES2901418T3 (es) | 2014-08-13 | 2022-03-22 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
NZ730334A (en) | 2014-09-11 | 2023-01-27 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
WO2016095204A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor antagonists |
WO2016095205A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
US10370380B2 (en) | 2015-11-23 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
KR20180107232A (ko) | 2016-02-12 | 2018-10-01 | 아스트라제네카 아베 | 오렉신 수용체 조정제로서의 할로-치환된 피페리딘 |
JP7066622B2 (ja) | 2016-03-10 | 2022-05-13 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン-2受容体アンタゴニストを用いてうつ病を治療する方法 |
EP3454857A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
CN107556266B (zh) * | 2017-09-12 | 2021-04-23 | 华南农业大学 | 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
ATE288904T1 (de) | 1998-06-18 | 2005-02-15 | Bristol Myers Squibb Co | Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen |
SE9803773D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
DE60043397D1 (de) | 1999-12-28 | 2010-01-07 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
AU779266B2 (en) * | 2000-05-11 | 2005-01-13 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
US20030176454A1 (en) * | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
JP4399256B2 (ja) * | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
EP1539747B1 (en) * | 2002-09-18 | 2006-11-02 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
KR20050097971A (ko) * | 2003-02-03 | 2005-10-10 | 씨브이 쎄러퓨틱스, 인코포레이티드 | A₁아데노신 수용체의 부분 및 전 작용제 |
WO2004096780A1 (en) * | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Quinoxalinone-3- one derivatives as orexin receptor antagonists |
MXPA05012281A (es) | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
WO2005115990A1 (ja) * | 2004-05-26 | 2005-12-08 | Eisai R & D Management Co., Ltd. | シンナミド化合物 |
WO2006058905A1 (en) | 2004-12-01 | 2006-06-08 | Devgen Nv | 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY |
US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
ES2328400T3 (es) | 2005-04-21 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias. |
EP1953151A4 (en) | 2005-11-18 | 2010-06-02 | Eisai R&D Man Co Ltd | SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF |
CA2628047A1 (en) | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamide derivative |
KR20080069221A (ko) * | 2005-11-24 | 2008-07-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모르폴린 타입의 신나미드 화합물 |
US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
AR059955A1 (es) | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide |
JPWO2007135970A1 (ja) | 2006-05-19 | 2009-10-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環系−シンナミド誘導体 |
US20100105904A1 (en) | 2006-05-19 | 2010-04-29 | Teiji Kimura | Urea type cinnamide derivative |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
US7737141B2 (en) | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
ES2357992T3 (es) * | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
ATE525375T1 (de) * | 2007-03-13 | 2011-10-15 | Merck Sharp & Dohme | Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 |
KR101138045B1 (ko) * | 2007-05-11 | 2012-04-24 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제로서의 헤트아릴아닐린 |
BRPI0906799A2 (pt) * | 2008-01-11 | 2015-07-14 | Hoffmann La Roche | Moduladores para amiloide beta |
-
2008
- 2008-12-11 AU AU2008340421A patent/AU2008340421B2/en not_active Ceased
- 2008-12-11 BR BRPI0821141-8A patent/BRPI0821141A2/pt not_active IP Right Cessation
- 2008-12-11 EP EP08863484A patent/EP2234999A1/en not_active Withdrawn
- 2008-12-11 CN CN200880122314.1A patent/CN101903372B/zh not_active Expired - Fee Related
- 2008-12-11 CA CA2705411A patent/CA2705411A1/en not_active Abandoned
- 2008-12-11 KR KR1020107013324A patent/KR101204213B1/ko not_active IP Right Cessation
- 2008-12-11 WO PCT/EP2008/067273 patent/WO2009080533A1/en active Application Filing
- 2008-12-11 JP JP2010538587A patent/JP5395808B2/ja not_active Expired - Fee Related
- 2008-12-15 US US12/334,559 patent/US7897627B2/en not_active Expired - Fee Related
- 2008-12-18 CL CL2008003787A patent/CL2008003787A1/es unknown
- 2008-12-18 PE PE2008002139A patent/PE20091173A1/es not_active Application Discontinuation
- 2008-12-18 TW TW097149466A patent/TW200930362A/zh unknown
- 2008-12-19 AR ARP080105570A patent/AR069849A1/es unknown
-
2010
- 2010-05-10 IL IL205665A patent/IL205665A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101903372A (zh) | 2010-12-01 |
TW200930362A (en) | 2009-07-16 |
US7897627B2 (en) | 2011-03-01 |
JP2011506534A (ja) | 2011-03-03 |
EP2234999A1 (en) | 2010-10-06 |
US20090163485A1 (en) | 2009-06-25 |
BRPI0821141A2 (pt) | 2015-06-16 |
CL2008003787A1 (es) | 2010-02-19 |
KR101204213B1 (ko) | 2012-11-26 |
KR20100082807A (ko) | 2010-07-19 |
AU2008340421B2 (en) | 2013-12-19 |
PE20091173A1 (es) | 2009-08-03 |
WO2009080533A1 (en) | 2009-07-02 |
JP5395808B2 (ja) | 2014-01-22 |
CN101903372B (zh) | 2014-06-18 |
AU2008340421A1 (en) | 2009-07-02 |
IL205665A0 (en) | 2010-11-30 |
IL205665A (en) | 2014-01-30 |
CA2705411A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069849A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
AR066509A1 (es) | Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide. | |
AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
AR071925A1 (es) | Malonamidas como antagonistas de orexina | |
AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
AR065718A1 (es) | Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos. | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
PE20080543A1 (es) | Nuevos derivados de fenilo, piridina y quinolina | |
AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
PE20040290A1 (es) | Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp | |
AR038419A1 (es) | Derivados de piridina y quinolina | |
PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
PE20121182A1 (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
AR054232A1 (es) | Derivados de piridina -2- carboxamida como antagonistas de mglur5 | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
AR092555A1 (es) | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
AR070635A1 (es) | DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS. | |
AR065904A1 (es) | Heterociclos como antagonistas de orexina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |